Amgen's average Accounts Receivable for the
three
months ended in Dec. 2024 was $7,050 Mil. Amgen's Revenue for the
three
months ended in Dec. 2024 was $9,086 Mil.
Hence, Amgen's Days Sales Outstanding for the
three
months ended in Dec. 2024 was 70.80.
The historical rank and industry rank for Amgen's Days Sales Outstanding or its related term are showing as below:
AMGN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.68 Med: 60.63 Max: 83.07
Current: 76.61
During the past 13 years, Amgen's highest Days Sales Outstanding was 83.07. The lowest was 46.68. And the median was 60.63.
AMGN's Days Sales Outstanding is ranked worse than 55.64% of 967
companies
in the Drug Manufacturers industry
Industry Median: 71.48
vs AMGN: 76.61
Amgen's Days Sales Outstanding
declined
from Dec. 2023 (74.67) to Dec. 2024 (70.80).
Amgen Days Sales Outstanding Historical Data
The historical data trend for Amgen's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amgen's Days Sales Outstanding
For the Drug Manufacturers - General subindustry, Amgen's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen's Days Sales Outstanding Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Amgen's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Amgen Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Amgen's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 